logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dennis J. Slamon

UCLA
H指数:126
被引数:10.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆

HR阳性/HER2阴性早期乳腺癌患者的辅助瑞博西lib联合非甾体类芳香化酶抑制剂治疗：NATALEE试验5年随访的有效性结局及更新后的总生存期☆

ESMO Open
IF8.3
2025-10-170
OAAI
J. Crown; D. Stroyakovskii; D.A. Yardley; C.-S. Huang; P.A. Fasching; A. Bardia; S. Chia; S.-A. Im; M. Martin; B. Xu; C.H. Barrios; M. Untch; R. Moroose; S.A. Hurvitz; G.N. Hortobagyi; D.J. Slamon; F. Visco; G. Spera; J.P. Zarate; D. Halligan; Z. Li; S. Loi
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

中间终点作为长期结局的替代指标在乳腺癌辅助化疗试验中的应用

ONCOLOGIST
IF4.2
2025-09-010
OAAI
Blasco, Andrea; Lopez-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martin, Miguel; Bermejo, Begona; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; Garcia-Saenz, Jose A.; Chan, Arlene; Guerrero-Zotano, Angel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesus; Slamon, Dennis
Predicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients

预测年轻乳腺癌患者接受化疗和抗HER2治疗后卵巢功能丧失

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
IF7.2
2025-09-013
OAAI
Lambertini, Matteo; Allegranza, Deirdre; Laubender, Ruediger P.; Harbeck, Nadia; Swain, Sandra M.; Geyer, Charles E.; Slamon, Dennis J.; Bobba, Gabriella; Lambertini, Chiara; de Haas, Sanne; Restuccia, Eleonora; Vaz-Luis, Ines; Cameron, David A.; Krop, Ian E.; Winer, Eric P.; Anderson, Richard A.
Phase II study of efficacy and safety of palbociclib in patients with recurrent ovarian cancer

帕博西利（palbociclib）在复发性卵巢癌患者中的有效性和安全性II期研究

International Journal of Gynecological Cancer
IF4.7
2025-07-280
OAAI
Gottfried E. Konecny; Tara M. Davidson; Coriolan L. Lebreton; Leah A. Marsh; Deandra K. Chetram; Hunter J. Atkinson; Melissa C. Larson; Ann L. Oberg; Nabilah Abdelaal; Jordyn Silverstein; Aminah Jatoi; Anita Washburn; Jill Burton; Sean Dowdy; Liying Zhang; Dorothy Hallberg; Victor E. Velculescu; Dennis J. Slamon; Andrea E. Wahner-Hendrickson
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2025-04-100
OAAI
Garcia-Saenz, Jose A.; Spera, Gonzalo; Pollan, Marina; Bermejo, Begona; Ruiz-Borrego, Manuel; Chan, Arlene; Martin, Miguel; Guerrero-Zotano, Angel; Calvo, Lourdes; Rodriguez-Lescure, Alvaro; Marin, Maria; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Oscar; Bezares, Susana; Slamon, Dennis
Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2L early breast cancer (EBC)

亚洲和非亚洲患者(pts)在NATALEE试验中，接受ribociclib(RIB)联合非甾体类芳香化酶抑制剂(NSAI)治疗人表皮生长因子受体2低表达激素受体阳性早期乳腺癌(EBC)的分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Xu, B.; Stroyakovskiy, D.; Sohn, J.; Park, Y. H.; Huang, C-S.; Lu, Y-S.; Jung, K. H.; Chan, A.; Zhang, J.; Lee, J.; Kim, J. H.; Chung, C-F.; Slamon, D.; Sakalosh, V.; Gao, M.; Amin, K.; Islam, S.; Im, S-A.
Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors

I期，两阶段，多中心首次人体（FIH）研究：TORL-1-23——一种新型靶向Claudin 6（CLDN6）的抗体药物偶联物（ADC），用于晚期实体瘤患者。

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Konecny, G. E.; Hendrickson, A. E. Wahner; Winterhoff, B.; Adjei, A. A.; Kung, A.; Miller, L-L.; Press, M. F.; Qazi, I.; Scholler, N.; Dokainish, H.; Letrent, S.; Slamon, D.
Ribociclib plus Endocrine Therapy in Early Breast Cancer
NEW ENGLAND JOURNAL OF MEDICINE
IF78.5
2024-03-2156
PRE
Slamon, Dennis; Lipatov, Oleg; Nowecki, Zbigniew; McAndrew, Nicholas; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A.; Huang, Chiun-Sheng; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Ruiz-Borrego, Manuel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Afenjar, Karen; Fresco, Rodrigo; Severin, Irene; Ji, Yan; Ghaznawi, Farhat; Li, Zheng; Zarate, Juan P.; Chakravartty, Arunava; Taran, Tetiana; Hortobagyi, Gabriel
Invasive diseaseefree survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HRD/HER2-early breast cancer (EBC)
ANNALS OF ONCOLOGY
IF65.4
2023-10-013
PRE
Bardia, A.; Hortobagyi, G. N.; Lipatov, O.; McAndrew, N. P.; Lacko, A.; Sohn, J.; Hart, L.; Crown, J. P.; Im, S-A.; Harbeck, N.; O'Shaughnessy, J.; Xu, B.; Barrios, C. H.; Moroose, R.; Gonzalez, V.; Fresco, R.; Ghaznawi, F.; Waters, S.; Chakravartty, A.; Slamon, D.
Health-related quality of life (HRQoL) in the phase III NATALEE study of adjuvant ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) vs NSAI alone in patients (pts) with HRD/HER2-early breast cancer (EBC)
ANNALS OF ONCOLOGY
IF65.4
2023-10-011
OAAI
Fasching, P. A.; Slamon, D.; Nowecki, Z.; Kukielka-Budny, B. D.; Stroyakovskiy, D.; Yardley, D.; Huang, C.; Chan, A.; Chia, S.; Martin, M.; Rugo, H. S.; Loi, S.; Hurvitz, S. A.; Untch, M.; Afenjar, K.; Fresco, R.; Danyliv, A.; Ferrusi, I.; Li, Z.; Hortobagyi, G. N.

研究方向

暂未获取到该数据
R
Richard S. Finn
H 指数:101论文数:764被引数:8.2万
N
Neil A. O’Brien
H 指数:27论文数:375被引数:2,269
S
Sara A. Hurvitz
H 指数:76论文数:713被引数:3.1万
J
Judy Dering
H 指数:26论文数:172被引数:5,482
D
Dylan Conklin
H 指数:13论文数:131被引数:2,663
J
John Crown
H 指数:88论文数:865被引数:3.9万
M
Michael F. Press
H 指数:91论文数:624被引数:5.5万
G
Gottfried E. Konecny
H 指数:58论文数:410被引数:2.0万
M
Martina S.J. McDermott
H 指数:17论文数:208被引数:1,454
C
Charles Ginther
H 指数:27论文数:152被引数:5,005